Introduction
Epilepsy prevalence in the general population ranges from 0.27 to 1.7%. 1 However, in patients with multiple sclerosis (MS), an average of 2.3% has been described (range 0.5-10.8%), 2 suggesting this association is not coincidental. These findings were confirmed recently in a population study that included more than 5000 MS patients. 3 The pathophysiological mechanisms that explain this association are still under investigation. Studies based on new magnetic resonance imaging (MRI) sequences have shown more cortical lesions and atrophy in patients affected by both disorders 4, 5 perhaps explaining the higher epilepsy prevalence in MS patients.
The aim of this study is to determine the prevalence of epilepsy in our MS patients and comprehend the possible underlying mechanisms involved.
Materials and methods
We retrospectively reviewed the records of all patients fulfilling MS diagnostic criteria or clinically isolated syndrome (CIS), 6 seen at the Multiple Sclerosis Center of the Pontifical Catholic University of Chile, between 2009 and 2012. The study protocol was approved by the Ethics Committee of the Faculty of Medicine. Epilepsy diagnosis and seizures types were established according to the classification of the International League Against Epilepsy (ILAE, 1981) . We evaluated the findings in standard interictal EEGs (international system 10/20 and activated with photo stimulation and hyperventilation) performed within the first week after the first seizure. We reviewed the incidence of cortical lesions in MRI (diffusion weighted image (DWI), fluid attenuated inversion recovery (FLAIR), double inversion recovery (DIR) and T1 with gadolinium, using 1.5 T with 5 mm thick slices, and 2.5 mm separation between cuts). We evaluated brain volume using manual measurements with ''NIH Image J'' public domain software available at the National Institute of Health homepage.
We performed cognitive evaluation using D-KEFS for verbal fluency, BTACT for processing speed and Digit Span from NeBHis for attention evaluation.
Gender, current age, age at onset, initial symptoms, clinical course and duration of MS, expanded disability scale status of Kurtzke (EDSS), immunomodulatory therapy and use of antiepileptic drugs (AED) were also analyzed.
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Fisher's test for dichotomous variables and nonparametric Mann-Whitney test for continuous variables were obtained using the SPSS Statistics 20.0 program. Differences were considered significant at p < 0.05.
Results

Clinical features
We found a total of 310 patients, 280 of them with definite diagnosis of MS and 30 of CIS. Ten patients (3.2%, 10/310), also have the diagnosis of epilepsy. In analyzing the demographic variables between groups of patients with and without epilepsy, we found no significant differences in gender, duration of disease, clinical course or EDSS. Both current age and age at MS onset were significantly lower in the group with epilepsy compared to the group without epilepsy (32 vs. 40 years, p = 0.04 and 25 vs. 32 years, p = 0.02, respectively). In addition, all patients with epilepsy and MS were receiving immunomodulatory therapy compared to 66% of MS patients without epilepsy (p = 0.03) ( Table 1) .
Patients with multiple sclerosis and epilepsy
Ten patients (5 men) met diagnostic criteria for epilepsy and MS/CIS. None had had seizures before MS diagnosis and they occurred as the first symptom (4 patients) or during the course of the disease. Partial onset with secondary generalization was the most frequent type of seizure (6 patients). Two patients had generalized tonic clonic seizures and another 2 had only partial seizures. Notably, 2 patients had convulsive status epilepticus during their evolution. Interictal EEG showed focal abnormalities in 4 patients. All patients had cortical lesions on MRI (supplementary figure 1). When comparing good versus poor epilepsy control (7 vs. 3 patients respectively), considering poor control as frequent seizures or status epilepticus, we found lower brain volumes (average 28% less volume, p = 0.01) and worse cognitive performance (32% worse scores, p = 0.03) in the last group (supplementary figure 2). All patients with epilepsy and MS were receiving immunomodulatory and anticonvulsant treatment ( Table 2) .
Supplementary material related to this article can be found, in the online version, at http://dx.doi.org/10.1016/j.seizure.2013. 09.008. 
Discussion
The epilepsy prevalence in our MS patients' cohort was 3.2%. This is the first description in Chile. This finding is similar to previous studies with larger number of patients. Catenoix described prevalence of 2% in a study that included 5041 patients with MS, 3 which is similar to the findings shown in a review of 29 clinical series, with a total of 17,239 MS patients and an average prevalence of seizures of 2.3% with a range from 0.5 to 10.8%. 2 It is noteworthy that all of our patients met diagnostic criteria for epilepsy and had no seizures before being diagnosed with MS. In this regard, most data found in the literature correspond to the prevalence of seizures, which might not reflect epilepsy prevalence which could be even lower. Adjusting the epilepsy prevalence to age, these values are about three times higher than those in the general population. 7, 8 However, prevalence found in our cohort may not accurately reflect our country statistics, due to the limited retrospective design we used, and because our hospital is a referral center for both MS and epilepsy in Chile.
In some cases, seizures may not be associated with MS as the sole cause. In Catenoix's series, only in 67 of the 102 patients who had had a seizure it was found that MS was the only probable cause. Some authors suggest that the occurrence of epilepsy in these patients could be correlated with the clinical course or severity of MS. However, we found no correlation with different clinical courses, EDSS, neither with the use of different immunomodulators, including interferon beta, as previously reported. 2 The pathophysiology basis of seizures in MS patients could be explained whether these occur during a relapse or regardless. 8 In one case, seizures are associated to inflammatory cortical lesions, as observed with DIR sequences. 5 As younger patients present with more inflammatory lesions, this could explain the fact that our cohort of patients was younger and had an earlier onset of MS, including seizures as the first manifestation of the demyelinating disease. 10 Additionally, all types of seizures have been described in patients with MS, being those with partial onset the most frequent (62-67%), corresponding to almost twice as observed in patients with epilepsy in general. 2, 3 The predominance of partial seizures and focal paroxysmal activity in the EEG supports the role of focal inflammatory lesions. Another scenario occurs, when cortical atrophy and neurodegeneration develop as the expression of the ongoing epileptogenic processes, as seen in patients experiencing seizures, regardless of a relapse. 8 Patients with poor epilepsy control (including status epilepticus) had significant lower brain volumes and worse cognitive performances as compared with those with good control. Although most patients with epilepsy and MS develop oligosymptomatic epilepsy, 11,12 the higher frequency of status epilepticus (20-30%) 8, 9 represents a relevant finding. While there are still no randomized clinical trials that demonstrate the superiority of a specific AED or that evaluate drugs that stop the underlying epileptogenic processes, the possibility of predicting poor epilepsy control could be a real breakthrough for prescribing long term AED treatment in these patients, making the attempt to halt the progression of brain atrophy and cognitive impairment.
Conclusions
Patients with epilepsy and MS have cortical inflammatory lesions that would explain focal onset seizures during relapses or as debut of MS. However, some patients build up numerous epileptogenic processes, developing seizures away from relapses, perpetuating neurodegeneration and cognitive impairment. These patients should be the center for new treatment strategies targeting the detention of the epileptogenic progression.
